#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Buspiron - a New Non-benzodiazepin Anxiolytic on our Market


Authors: R. Honzák;  H. Kurzová
Authors‘ workplace: Ústav všeobecného lékařství 1. LF UK, Praha, přednostka MUDr. H. Kurzová
Published in: Prakt. Lék. 2001; (7): 391-396
Category:

Overview

The authors inform readers on the pharmacological and clinical profile of a new anxiolytic onthe market. Buspiron is indicated in anxious disorders in particular in generalized anxietydisorder. Buspiron has a clinical effect similar to that of currently used benzodiazepineanxiolytics. Contrary to them it has several advantages: it does not affect psychomotorfunctions, does not cause sedation, does not potentiate substances which evoke central depression (alcohol, benzodiazepines and some other psychopharmaceutical preparations), it does notcause habituation, it has a minimumof drug interactions and is well tolerated. Its disadvantageis the late onset of the anxiolytic effect which develops after two weeks or later.

Key words:
buspiron - anxiety disorders - anxiolytics - benzodiazepines.

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
General practitioner for children and adolescents General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#